High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.
about
The technology of MRI — the next 10 years?Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug developmentOligonucleotide therapeutic approaches for Huntington diseaseEarly alterations of brain cellular energy homeostasis in Huntington disease modelsTherapeutic interventions for disease progression in Huntington's diseaseTherapeutic use of creatine in brain or heart ischemia: available data and future perspectives.A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosisCardiac dysfunction in the R6/2 mouse model of Huntington's diseaseA Prophylactic Role for Creatine in Hypoxia?Emerging drugs for Parkinson's disease.A systematic review of the treatment studies in Huntington's disease since 1990.Huntington's disease: pathological mechanisms and therapeutic strategies.Huntington's disease: progress and potential in the field.Neuroprotection for Huntington's disease: ready, set, slowTherapy development for ALS: lessons learned and path forward.ALS drug development: reflections from the past and a way forwardEndogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines.Molecular mechanisms and potential therapeutical targets in Huntington's disease.Energy deficit in Huntington disease: why it matters.Creatine in mouse models of neurodegeneration and aging.Pharmacologic approaches to the treatment of Huntington's disease.Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q.The CREST-E study of creatine for Huntington disease: A randomized controlled trial.A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers.Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.Recombinant AAV Viral Vectors Serotype 1, 2, and 5 Mediate Differential Gene Transfer Efficiency in Rat Striatal Fetal Grafts.Commentary on ‘A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS’
P2860
Q22065264-75F2F8D9-C2CE-497F-82C7-1F3602AC5A76Q22241837-44719BB3-8CD4-4A6E-946E-0CF22C09E885Q22306293-3E30E393-0164-40B2-8357-281E1913CF04Q23912810-71E5543F-73FC-4A82-9550-DEA16F392B7EQ24239973-AF1B7CF7-A340-4116-B306-4607E193F2B9Q34089086-38B960CD-07C7-42F5-AE49-B945284D2824Q34610044-BB2DA6B0-16FA-42F6-B386-794903ED9B28Q35745626-1DEF1FF2-1EB5-44C2-8614-008AF0750FEBQ35772902-F958D3AC-549E-4762-86B1-07137A2A2408Q36580572-DF538BE7-477A-43BC-9094-D6D02470536CQ36719669-A4BF7026-59E3-4F45-827F-269A0B211676Q36822322-B9FF6408-BE15-4DBE-A69A-4E65F559695AQ37016096-1F101947-87FB-4CD3-A727-DFFA3A998B30Q37131243-8E24EED9-8469-4767-A16A-65FD0912608EQ37198692-6CEA3E22-1ED6-438D-AFFB-CDE3CB69F467Q37329513-06CE6DAE-ADE8-4936-8A56-D55E45A7A695Q37580731-F0B8A06C-756B-4049-99C6-E64B2FCE9A1FQ37776087-4DEA4DEA-5FE2-4E1F-898E-3B09F8FA7AE2Q37834195-445E9190-20ED-438F-B7E7-9F8B5ECB2F29Q37851389-BAE66FE9-927E-4015-B4DD-FC1127FF5986Q37945478-22A53ED1-E541-46FF-BA89-397CB7EC9760Q37965763-33E03896-DCAD-4ADD-89C9-5CC27F09D78DQ38374092-D5A5AF7B-7188-4508-8DAB-82F335C997F5Q39037892-1EB94E21-E1DC-4637-9D39-EE8963C09751Q40027470-4230F91D-86F4-4055-98D0-5ABA0196A9F0Q45303980-0ADC5A99-820B-4210-8565-70B5FA670F85Q58125457-E83D1A4B-35ED-4D19-B505-0BA81B8C2754
P2860
High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.
@en
High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.
@nl
type
label
High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.
@en
High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.
@nl
prefLabel
High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.
@en
High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.
@nl
P2093
P50
P1433
P1476
High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study
@en
P2093
Rajagopalan B
Schapira AH
P304
P356
10.1212/01.WNL.0000160388.96242.77
P407
P577
2005-05-01T00:00:00Z